Ph III study to evaluate the safety of ALN-TTR02 in TTR-Medicated Polyneuropathy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Alnylam Pharmaceuticals
Start Date
November 1, 2014
End Date
August 2, 2018
Administered By
Duke Cancer Institute
Awarded By
Alnylam Pharmaceuticals
Start Date
November 1, 2014
End Date
August 2, 2018